Fig. 1

Lipidomic patterns in advanced NSCLC individuals pre and post administration of PD-1/PD-L1 inhibitors along with anlotinib. A The PLS-DA analysis was performed on advanced NSCLC patients in the PR group (n = 6). The non-treated PR group was represented by ‘1’ and the anlotinib along with PD-1/PD-L1 inhibitors-treated PR group was represented by ‘2’. B Correlation analysis was carried out on PR group subjects with advanced NSCLC to examine the associations among distinct lipids. Various colors were utilized to depict the correlation strength, employing the Pearson’s correlation coefficient. C The PLS-DA analysis was carried out on SD group subjects with advanced NSCLC patients (n = 17). The non-treated PR group was represented by ‘1’ and anlotinib along with PD-1/PD-L1 inhibitor -treated SD group was represented by ‘2’. D Correlation analysis was carried out on SD group subjects with advanced NSCLC to examine the associations among distinct lipids. Various colors were utilized to depict the correlation strength, employing the Pearson’s correlation coefficient. E The PLS-DA analysis was performed on advanced NSCLC patients in the PD group (n = 7). The non-treated PD group was represented by ‘1’ and anlotinib along with PD-1/PD-L1 inhibitor-treated PD group was represented by ‘2’. F Correlation analysis was performed on advanced NSCLC patients in the PD group to investigate the significantly diverse lipids. The level of Pearson’s correlation coefficient was represented using various colors